LIVIVO - Search results -

Search results

Result 1 - 10 of total 32

Search options

Article ; Online: Biological therapies in the prevention of maternal mortality.

Ljubić, Aleksandar / Bozanovic, Tatjana / Piperski, Vesna / Đurić, Emilija / Begovic, Aleksa / Sikiraš, Marina / Perovic, Andjela / Vukovic, Jovana / Abazović, Džihan

Journal of perinatal medicine

2022 Volume 51, Issue 2, Page(s) 253–260

Abstract: Although the maternal mortality rate has decreased and significant improvements have been made in maternal care, maternal death remains one of the substantial problems of our society. The leading causes of maternal death are postpartum hemorrhage, the ... ...

Abstract	Although the maternal mortality rate has decreased and significant improvements have been made in maternal care, maternal death remains one of the substantial problems of our society. The leading causes of maternal death are postpartum hemorrhage, the most important cause of death in developing countries, and preeclampsia and venous thromboembolism, which are more prevalent in developed countries. To treat these conditions, a variety of therapeutic approaches, including pharmacologic agents and surgical techniques, have been adopted. However, a certain number of pregnant women do not respond to any of these options. That is the main reason for developing new therapeutic approaches. Biological medications are isolated from natural sources or produced by biotechnology methods. Heparin is already successfully used in the therapy of deep venous thrombosis and pulmonary embolism. Blood derivatives, used in an autologous or allogenic manner, have proven to be efficacious in achieving hemostasis in postpartum hemorrhage. Mesenchymal stem cells, alpha-1-microglobulin, and antithrombin exhibit promising results in the treatment of preeclampsia in experimental models. However, it is essential to evaluate these novel approaches' efficacy and safety profile throughout clinical trials before they can become a standard part of patient care.
MeSH term(s)	Female ; Pregnancy ; Humans ; Maternal Mortality ; Postpartum Hemorrhage/prevention & control ; Postpartum Hemorrhage/drug therapy ; Maternal Death ; Pre-Eclampsia/prevention & control ; Pre-Eclampsia/drug therapy ; Anticoagulants/therapeutic use ; Venous Thromboembolism/prevention & control ; Biological Therapy
Chemical Substances	Anticoagulants
Language	English
Publishing date	2022-11-28
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	123512-6
ISSN	1619-3997 ; 0300-5577 ; 0936-174X
ISSN (online)	1619-3997
ISSN	0300-5577 ; 0936-174X
DOI	10.1515/jpm-2022-0403
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 926: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy.

Gutic, Bojana / Bozanovic, Tatjana / Mandic, Aljosa / Dugalic, Stefan / Todorovic, Jovana / Stanisavljevic, Dejana / Dugalic, Miroslava Gojnic / Sengul, Demet / Detanac, Dzenana A / Sengul, Ilker / Detanac, Dzemail / Soares, José Maria

Clinics (Sao Paulo, Brazil)

2023 Volume 78, Page(s) 100177

Abstract: Programmed Cell Death-1 (PCD-1) is a key immune checkpoint receptor, which mainly expresses on activated T, B, Dendritic (DC), Natural Killer (NK), and Treg cells. On the surface of activated T-cells, PCD-1 expression is upregulated after the recognition ...

Abstract	Programmed Cell Death-1 (PCD-1) is a key immune checkpoint receptor, which mainly expresses on activated T, B, Dendritic (DC), Natural Killer (NK), and Treg cells. On the surface of activated T-cells, PCD-1 expression is upregulated after the recognition of peripherals antigens by T cells; subsequently, the elevated binding of PD-1 to Programmed Death Ligand-1 (PD-L1) and Programmed Death Ligand-2 (PD-L2) becomes a key step for downstream inhibitory signaling. Although the role of PD-L1 has been evaluated more thoroughly by clinical research, and PD-L1 has also been used more widely in the clinical setting, PD-L2 also plays an important role in the negative regulation of T-cells, one of the necessary conditions that lead to immune tolerance. Expression of PD-L1 either in tumors or in infiltrating immune cells has been verified predominantly by Immunohistochemistry (IHC) in a variety of tumors, suggesting a role for the PD-1/PD-L1 axis as a prognostic trait and therapeutic target across multiple histotypes. The complex interplay between these factors plays a major role in the diffusion and clinical application of PD-L1 IHC assays as predictive biomarkers of response to PD-1/PD-L1 inhibitors. Checkpoint blockades are registered for the treatment of various cancers, including gynecological malignancies.
MeSH term(s)	Humans ; B7-H1 Antigen/metabolism ; B7-H1 Antigen/therapeutic use ; Ligands ; Programmed Cell Death 1 Receptor/metabolism ; Programmed Cell Death 1 Receptor/therapeutic use ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Immunotherapy ; Apoptosis
Chemical Substances	B7-H1 Antigen ; Ligands ; Programmed Cell Death 1 Receptor
Language	English
Publishing date	2023-03-14
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2182801-5
ISSN	1980-5322 ; 1807-5932
ISSN (online)	1980-5322
ISSN	1807-5932
DOI	10.1016/j.clinsp.2023.100177
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 404: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Preliminary outcomes of five-year survival for ovarian malignancies in profiled Serbian Oncology Centre.

Gutic, Bojana / Bozanovic, Tatjana / Mandic, Aljosa / Dugalic, Stefan / Todorovic, Jovana / Dugalic, Miroslava Gojnic / Sengul, Demet / Detanac, Dzenana A / Sengul, Ilker / Detanac, Dzemail / Kesicioglu, Tugrul / Soares Junior, José Maria

Clinics (Sao Paulo, Brazil)

2023 Volume 78, Page(s) 100204

Abstract: Objective: The present study purposed to determine characteristics of ovarian carcinoma and to analyze predictors of survival in patients with ovarian carcinoma.: Method: A retrospective cohort study was conducted including the patients with ... ...

Abstract	Objective: The present study purposed to determine characteristics of ovarian carcinoma and to analyze predictors of survival in patients with ovarian carcinoma. Method: A retrospective cohort study was conducted including the patients with diagnosed ovarian carcinoma treated at the Clinic for Operative Oncology, Oncology Institute of Vojvodina in the period from January 2012 to December 2016. Seventy-two women with ovarian carcinoma were included in the analysis. The data about the histological type of tumor, disease stage, treatment, lymphatic infiltration, and surgical procedure were collected retrospectively, using the database of the institution where the research was conducted (BirPis 21 SRC Infonet DOO ‒ Information System Oncology Institute of Vojvodina). Descriptive statistics and multivariate analysis using Cox proportional hazards model were performed. Results: The univariate Cox regression analysis identified histology, tumor grade, FIGO (International Federation of Gynecology and Obstetrics) stage, NACT (Neoadjuvant Chemotherapy), number of therapy cycles, type of surgery, and chemotherapy response as independent predictors of mortality. Finally, the type of tumor and chemotherapy response had an increased hazard ratio for mortality in the multivariate Cox regression model. Herewith, the percentage of high-grade, advanced-stage ovarian cancer patients with complete response to chemotherapy, absence of recurrent disease, and lymphovascular space invasion were significant predictors of survival in patients with ovarian carcinoma. Conclusions: Herein, emerging data regarding precision medicine and molecular-based personalized treatments are promising and will likely modify the way the authors provide multiple lines of treatments in the near future.
MeSH term(s)	Humans ; Female ; Retrospective Studies ; Serbia/epidemiology ; Neoplasm Staging ; Ovarian Neoplasms ; Carcinoma, Ovarian Epithelial ; Neoadjuvant Therapy ; Chemotherapy, Adjuvant
Language	English
Publishing date	2023-05-04
Publishing country	United States
Document type	Journal Article
ZDB-ID	2182801-5
ISSN	1980-5322 ; 1807-5932
ISSN (online)	1980-5322
ISSN	1807-5932
DOI	10.1016/j.clinsp.2023.100204
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 404: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Influence of Autologous

Tinjić, Suada / Abazović, Džihan / Ljubić, Dušica / Vojvodić, Danilo / Božanović, Tatjana / Ibrišimović, Mirza / Marković, Sergije / Ljubić, Aleksandar

International journal of fertility & sterility

2021 Volume 15, Issue 3, Page(s) 178–188

Abstract: Background: Premature ovarian failure (POF) can be found in 1% of women at the age of 35-40, mostly due to unknown causes. PI3K-Akt signaling is associated with both ovarian function and growth of primordial follicles. In this study, we examined the ... ...

Abstract	Background: Premature ovarian failure (POF) can be found in 1% of women at the age of 35-40, mostly due to unknown causes. PI3K-Akt signaling is associated with both ovarian function and growth of primordial follicles. In this study, we examined the effects of autologous Materials and methods: The longitudinal prospective observational study included 50 patients (between 30 and 50 years) with a diagnosis of POF and infertility. This multicenter study was performed at Jevremova Special Hospital in Belgrade, Saint James Hospital (Malta), and Remedica Skoplje Hospital, between 2015 and 2018. All patients went through numerous laboratory testings, including hormonal status. The autologous bone marrow mesenchymal stem cells (BMSCs) and growth factors were used in combination for activation of ovarian tissue before its re-transplantation. The software package SPSS 20.0 was used for statistical analysis of the results. Results: Differences in follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and progesterone (PG) hormone concentrations before and after 3, 6, and 12 months post-transplantation were tested in correlation with the volume of transplanted ovarian tissue. A significant correlation (P=0.029) was found between the change in E2 level after 3 months and the volume of re-transplanted tissues. Also after re-transplantation, 64% of the patients had follicles resulting in aspiration of oocytes in 25% of positive women with follicles. Conclusion: The SEGOVA method could potentially solve many human reproductive problems in the future due to the large number of patients diagnosed with POF, as well asthe possibility of delaying menopause, thus improving the quality of life and general health (Registration number: NCT04009473).
Language	English
Publishing date	2021-06-22
Publishing country	Iran
Document type	Journal Article
ZDB-ID	2570865-X
ISSN	2008-0778 ; 2008-076X
ISSN (online)	2008-0778
ISSN	2008-076X
DOI	10.22074/IJFS.2020.134678
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Endometrial stromal sarcoma with intracaval extension at initial presentation.

Boskovic, V / Bozanovic, T / Ljubic, A / Likic-Ladjevic, I / Janjic, T / Milicevic, S

European journal of gynaecological oncology

2013 Volume 34, Issue 3, Page(s) 280–281

Abstract: Endometrial stromal sarcoma (ESS) is a rare uterine neoplasm. Tumor involvement of the large vessels is extremely rare. This is a case report of ESS with tumor invasion of the inferior vena cava at initial presentation. ...

Abstract	Endometrial stromal sarcoma (ESS) is a rare uterine neoplasm. Tumor involvement of the large vessels is extremely rare. This is a case report of ESS with tumor invasion of the inferior vena cava at initial presentation.
MeSH term(s)	Endometrial Neoplasms/pathology ; Female ; Humans ; Magnetic Resonance Imaging ; Middle Aged ; Sarcoma, Endometrial Stromal/pathology ; Vena Cava, Inferior/pathology
Language	English
Publishing date	2013-07-19
Publishing country	China
Document type	Case Reports ; Journal Article
ZDB-ID	604589-3
ISSN	0392-2936
ISSN	0392-2936
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1679: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer.

Batman, Samantha / Matsuo, Koji / Mhawech-Fauceglia, Paulette / Munro, Elizabeth / Weisenberger, Mercedes / Allen, Allison / Joshi, Sonali / Machida, Hiroko / Matsuzaki, Shinya / Bozanovic, Tatjana / Pejovic, Tanja

Cancers

2021 Volume 13, Issue 8

Abstract: Background: Targeting DNA repair and immune checkpoint pathways has been the focus of multiple clinical trials. In this study, we explore the association between DNA repair proteins, immune response markers, and clinical outcome in women with EOC.: ... ...

Abstract	Background: Targeting DNA repair and immune checkpoint pathways has been the focus of multiple clinical trials. In this study, we explore the association between DNA repair proteins, immune response markers, and clinical outcome in women with EOC. Methods: Immunohistochemical analysis of TMA with 181 EOC samples was used to determine expression levels for DNA repair proteins (PARP, PTEN, p53, H2Ax, FANCD2, and ATM) and immune-markers (CD4, CD8, CD68, PD-L2, PD-L1, and FOXP3). Biomarker expression was correlated to clinical data. Prognostic discriminatory ability was assessed per the combination of biomarkers. Results: Tumor immunity biomarkers correlated with HRD biomarkers. High PD-L2 was significantly associated with high expression of CD8 ( Conclusions: Increased PD-L2 expression is a prognostic marker of decreased survival in EOC. Interaction between tumor DNA repair and microenvironment determines tumor progression and survival.
Language	English
Publishing date	2021-04-20
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers13081972
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Professionally responsible management of gynecologic cancer in pregnancy when clinical resources are unavoidably limited.

Božanović, Tatjana / Pejović, Tanja / Chervenak, Frank A / McCullough, Laurence / Ljubić, Aleksandar

Journal of perinatal medicine

2017 Volume 46, Issue 7, Page(s) 811–813

MeSH term(s)	Developed Countries ; Developing Countries ; Evidence-Based Practice/ethics ; Female ; Genital Neoplasms, Female/complications ; Genital Neoplasms, Female/therapy ; Humans ; Patient Care Team/ethics ; Pregnancy ; Pregnancy Complications, Neoplastic/therapy
Language	English
Publishing date	2017-12-21
Publishing country	Germany
Document type	Journal Article
ZDB-ID	123512-6
ISSN	1619-3997 ; 0300-5577 ; 0936-174X
ISSN (online)	1619-3997
ISSN	0300-5577 ; 0936-174X
DOI	10.1515/jpm-2017-0358
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 926: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Oncology treatment improvement--our experience in Serbia.

Bozanović, T / Zizić, V / Apostolović, M / Vidaković, S / Aksam, S / Bosković, V / Bajec, Dj / Kotlica, B K

European journal of gynaecological oncology

2012 Volume 32, Issue 6, Page(s) 665–666

Abstract: Objectives: To determine weather structural changes by a tumor board made any difference in quality of treatment for oncology patients.: Material and method: Current management of our hospital initiated structural changes in the tumor board in ... ...

Abstract	Objectives: To determine weather structural changes by a tumor board made any difference in quality of treatment for oncology patients. Material and method: Current management of our hospital initiated structural changes in the tumor board in January 2010 and improvement was measured through comparing the clinical staging of cervical cancer to previous tumor board results. Results: 365 patients were seen by a multidisciplinary tumor board from January to December of 2010. There were 146 cases of cervical cancer. 87 were staged as Ib-IIa for radical surgery, 59 patients were staged as advanced stage of disease and RT was proposed as well as combined radio-chemotherapy in some cases. Conclusion: Structural changes in the tumor board have made a significant improvement in the oncology care of our patients, primarily because of a multidisciplinary approach to gynecological malignancies and additional imaging performed in all cases of cervical cancer for better insight in the spread of the disease.
MeSH term(s)	Combined Modality Therapy ; Female ; Genital Neoplasms, Female/pathology ; Genital Neoplasms, Female/therapy ; Humans ; Neoplasm Staging ; Serbia
Language	English
Publishing date	2012-02-03
Publishing country	China
Document type	Journal Article
ZDB-ID	604589-3
ISSN	0392-2936
ISSN	0392-2936
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1679: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Uspesno lecenje primarne mijelofibroze s trombocitozom u trudnoći primenom alfa-interferona.

Gotić, M / Cvetković, M / Bozanović, T / Cemerikić, V

Srpski arhiv za celokupno lekarstvo

2001 Volume 129, Issue 11-12, Page(s) 304–308

Abstract: Primary myelofibrosis is predominantly a disease of old age, poor prognosis and no curable treatment. Thrombocytosis was observed in only 12% of patients. To our knowledge, there is only one reported case of a young woman with primary myelofibrosis who ... ...

Title translation	Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon.
Abstract	Primary myelofibrosis is predominantly a disease of old age, poor prognosis and no curable treatment. Thrombocytosis was observed in only 12% of patients. To our knowledge, there is only one reported case of a young woman with primary myelofibrosis who had a term pregnancy [1]. We report on a 29-year-old woman with thrombocytosis and medical history of two miscarriages in the last 2 years, the iirst at 30 weeks of gestation and the second at 27 weeks. Multiple placental infarctions were observed. She was without symptoms but with moderate splenomegaly 4.5 cm below left costal margin). The platelet count was 651 x 10(9)/L, WBC 7.2 x 10(9)/L with normal differential formula, and haemoglobin level 12 g/dl. Bone marrow biopsy showed fibrotic phase of primary myelofibrosis, with hyperplasia of megacaryocytes, decreased numbers of erythroid and granulocytic cells, and increased amounts of reticulin fibres. Cyctogenetic examination of the bone marrow showed normal female caryotype. Increased numbers of progenitors CFU-Mk, CFU-GM and BFU-E were observed in peripheral blood, and decreased numbers in bone marrow cultures. As the patient wished to become pregnant, the treatment with interferon-a (Roferon A) was started at a dose of 3 MU s.c., three times per week. The platelet count rapidly decreased at a level of 260-370 x 10(9)/L. The pregnancy was diagnosed 5 months later. At the 24 week of pregnancy, platelet count raised to 690 x 10(9)/l and the dose of interferon-a was augmented, 3 MU every day, until delivery. Foetal growth and placental circulation were monitored by serial ultrasonography. At the end of 34 weeks of pregnancy, it was noted that placental flow became insufficient, and after foetal lung maturity was stimulated with dexamethasone, Cesarean section was performed. Male baby was born, weighting 2000 g, with respiratory distress syndrome. This complication was successfully treated, and the child is now one year old, with normal growth and development. The mother is still on therapy with interferon-a, 3 MU, three times a week, and the last blood count was as follows: haemoglobin 10.7 g/dl, WBC 6.1 x 10(9)/L and platelet comt 437 x 10(9)/L. In conclusion, according to the clinical results of interferon-d in thrombocytosis and experimental studies which showed the absence of placental transfer of interferon-d, this therapy could be recommended to women with primary myelofibrosis who wish to have a baby.
MeSH term(s)	Adult ; Female ; Humans ; Interferon-alpha/therapeutic use ; Pregnancy ; Pregnancy Complications/drug therapy ; Pregnancy Complications, Hematologic/drug therapy ; Primary Myelofibrosis/complications ; Primary Myelofibrosis/drug therapy ; Recombinant Proteins ; Thrombocytosis/blood ; Thrombocytosis/complications ; Thrombocytosis/drug therapy
Chemical Substances	Interferon-alpha ; Recombinant Proteins ; interferon alfa-2a (47RRR83SK7)
Language	Serbian
Publishing date	2001-11
Publishing country	Serbia
Document type	Case Reports ; Journal Article
ZDB-ID	128567-1
ISSN	0370-8179 ; 0354-2793 ; 0049-0210
ISSN	0370-8179 ; 0354-2793 ; 0049-0210
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 248: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 556: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Synchronous primary tumors: appendiceal and ovarian cancer--case report.

Bozanović, T / Ljubić, A / Momcilov, P / Mostić, T / Vojvodić, L / Vidaković, S

European journal of gynaecological oncology

2008 Volume 30, Issue 2, Page(s) 237–238

Abstract: A 64-year-old women was operated on for acute abdomen and both appendiceal and ovarian tumors were found. Histology revealed synchronous adenocarcinoma of the appendix and serous pappillary carcinoma of the right ovary. The patient was given adjuvant ... ...

Abstract	A 64-year-old women was operated on for acute abdomen and both appendiceal and ovarian tumors were found. Histology revealed synchronous adenocarcinoma of the appendix and serous pappillary carcinoma of the right ovary. The patient was given adjuvant chemotherapy and received six cycles of cisplatinum. Regular follow-up showed no recurrence of the two synchronous primary tumors. A rare case of synchronous primary tumors of appendiceal and ovarian origin is reported. The tumors proved to be difficult to treat requiring several combined medical therapies, including surgery, chemo- and radiotherapy.
MeSH term(s)	Adenocarcinoma/pathology ; Appendiceal Neoplasms/pathology ; Carcinoma, Papillary/pathology ; Female ; Humans ; Middle Aged ; Neoplasms, Multiple Primary/pathology ; Ovarian Neoplasms/pathology
Language	English
Publishing date	2008-09-16
Publishing country	China
Document type	Case Reports ; Journal Article
ZDB-ID	604589-3
ISSN	0392-2936
ISSN	0392-2936
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1679: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito